Short Interest in ASP Isotopes Inc. (NASDAQ:ASPI) Expands By 86.8%

ASP Isotopes Inc. (NASDAQ:ASPI) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 2,840,000 shares, an increase of 86.8% from the June 15th total of 1,520,000 shares. Currently, 10.3% of the company’s stock are short sold. Based on an average daily volume of 947,200 shares, the short-interest ratio is presently 3.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price objective on shares of ASP Isotopes from $5.25 to $5.50 and gave the company a “buy” rating in a research report on Wednesday, April 17th.

ASP Isotopes Price Performance

Shares of NASDAQ ASPI opened at $3.47 on Friday. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 1.70. The business’s 50 day moving average price is $3.98 and its two-hundred day moving average price is $3.41. The company has a market cap of $179.62 million, a PE ratio of -6.55 and a beta of 5.12. ASP Isotopes has a twelve month low of $0.58 and a twelve month high of $5.67.

ASP Isotopes (NASDAQ:ASPI) last posted its earnings results on Wednesday, May 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.84 million during the quarter. On average, analysts predict that ASP Isotopes will post -0.11 EPS for the current year.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, Director Robert John Andrew Ryan purchased 9,500 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were purchased at an average cost of $3.42 per share, with a total value of $32,490.00. Following the transaction, the director now directly owns 546,555 shares of the company’s stock, valued at approximately $1,869,218.10. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Robert John Andrew Ryan purchased 9,500 shares of the stock in a transaction on Thursday, April 25th. The shares were purchased at an average price of $3.42 per share, with a total value of $32,490.00. Following the transaction, the director now directly owns 546,555 shares of the company’s stock, valued at $1,869,218.10. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Ak Jensen Investment Managemen acquired 61,849 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were bought at an average price of $3.40 per share, for a total transaction of $210,286.60. Following the purchase, the insider now owns 6,678,723 shares in the company, valued at $22,707,658.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 145,662 shares of company stock valued at $470,078. Corporate insiders own 26.30% of the company’s stock.

Hedge Funds Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of ASP Isotopes by 479.1% during the 1st quarter. Vanguard Group Inc. now owns 1,021,019 shares of the company’s stock worth $4,217,000 after buying an additional 844,705 shares during the last quarter. Rathbones Group PLC bought a new position in ASP Isotopes in the 4th quarter valued at about $272,000. Virtu Financial LLC lifted its position in ASP Isotopes by 477.0% during the first quarter. Virtu Financial LLC now owns 83,677 shares of the company’s stock worth $346,000 after acquiring an additional 69,176 shares during the last quarter. Finally, HTLF Bank bought a new stake in shares of ASP Isotopes during the fourth quarter worth approximately $141,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.